Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Lu, Janice ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; CDK4 CDK6 inhibitor; Palbociclib

Indexed keywords

ABEMACICLIB; ALPELISIB; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; PALBOCICLIB; PLACEBO; RIBOCICLIB; ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; FEBRILE NEUTROPENIA; HUMAN; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PIPERAZINES; PYRIDINES;

EID: 84939181197     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0194-5     Document Type: Article

References (20)

1. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-9.
2. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.
3. Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Experimental Hematol Oncol. 2014;3:23.
4. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.
5. Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.
6. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59.
7. Finn R, Dering J, Conklin D, Kalous O, Cohen D, Desai A, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
8. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
9. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in hormone-receptor-positive advanced breast cancer. The New England journal of medicine 2015(June 1): doi: 10.1056/NEJMoa1505270.
10. Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther. 2013;12(11 Supplement):R02.
11. Zhang Y-X, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13(9):2184-93.
12. Munster PN, Hamilton EP, Estevez LG, De Boer RH, Mayer IA, Campone M, et al. Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2-breast cancer. ASCO Meeting Abstracts. 2014;32(26-suppl):143.
13. Munster PN, Hamilton EP, Franklin C, Bhansali S, Wan K, Hewes B, et al. Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2- BC). ASCO Meeting Abstracts. 2014;32(15-suppl):533.
14. Tripathy D, Bardia A, Hurvitz SA, Harbeck N, Colleoni M, Franke FA, et al. Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7. ASCO Meeting Abstracts. 2015;33(15-suppl):TPS625.
15. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig New Drugs. 2014;32(5):825-37.
16. Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, et al. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res. 2014;20(14):3763-74.
17. Shapiro G, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. ASCO Meeting Abstracts. 2013;31(15-suppl):2500.
18. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. ASCO Meeting Abstracts. 2014;32(15-suppl):534.
19. Goetz MP, Toi M, Klise S, Frenzel M, Bourayou N, Di Leo A. MONARCH 3: a randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2015;33(15-suppl):TPS624.
20. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435-44.